Collegium to Acquire BioDelivery Sciences for ~ $604M
Shots:
- Collegium commences a tender offer to acquire all outstanding shares of BDSI at $5.60 per share in an all-cash transaction making a total deal value of $604M. It represents 54% premium to BDSI common stock’s closing price of $3.64 on Feb 11, 2022
- After the completion of the tender offer, Collegium to acquire all remaining shares at the same price of $5.60 per share via second step merger. The transaction is expected to be completed in Q1’22
- The addition of BDSI's Belbuca which is a schedule III opioid product complements Collegium's portfolio of pain products. BDSI other product includes Symproic and Elyxyb
Ref: Globe Newswire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com